Patents by Inventor Howard Benjamin
Howard Benjamin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9942293Abstract: Methods and systems for integrated communications are pro-vided. In one embodiment, a user input is received via a user interface. Media data is received in response to receiving the user input. The media data is streamed to one or more communication system users. In some embodiments, the media data is posted to a shared virtual space associated with a communication system channel. Other methods and systems are described.Type: GrantFiled: April 11, 2016Date of Patent: April 10, 2018Assignee: Microsoft Technology Licensing, LLCInventors: Raymond Edward Ozzie, Howard Benjamin Nager, Neil Bousquet Ozzie, Matthew Jason Pope, Ransom Lloyd Richardson, Richard Zack Speyer
-
Publication number: 20160226940Abstract: Methods and systems for integrated communications are pro-vided. In one embodiment, a user input is received via a user interface. Media data is received in response to receiving the user input. The media data is streamed to one or more communication system users. In some embodiments, the media data is posted to a shared virtual space associated with a communication system channel. Other methods and systems are described.Type: ApplicationFiled: April 11, 2016Publication date: August 4, 2016Inventors: Raymond Edward Ozzie, Howard Benjamin Nager, Neil Bousquet Ozzie, Matthew Jason Pope, Ransom Lloyd Richardson, Richard Zack Speyer
-
Patent number: 9313633Abstract: Methods and systems for integrated communications are provided. In one embodiment, a user input is received via a user interface. Media data is received in response to receiving the user input. The media data is streamed to one or more communication system users. In some embodiments, the media data is posted to a shared virtual space associated with a communication system channel. Other methods and systems are described.Type: GrantFiled: October 10, 2012Date of Patent: April 12, 2016Assignee: Talko Inc.Inventors: Raymond Edward Ozzie, Howard Benjamin Nager, Neil Bousquet Ozzie, Matthew Jason Pope, Ransom Lloyd Richardson, Richard Zack Speyer
-
Patent number: 8948567Abstract: A time-shifted digital content item is played via a playback screen, and an updateable companion timeline associated with the time-shifted digital content item is accessed. The updateable companion timeline includes one or more timeline events, and each timeline event has a trigger time corresponding to a playback time in the time-shifted digital content item. Responsive to reaching a playback time that matches a trigger time of one of the one or more timeline events during playback of the time-shifted digital content item, the timeline event having that trigger time is rendered.Type: GrantFiled: September 29, 2011Date of Patent: February 3, 2015Assignee: Microsoft Technology Licensing, LLCInventors: Matthew Fuller Sly, Jeffrey Lupien, Keh-Li Sheng, Howard Benjamin Nager
-
Publication number: 20120321275Abstract: A time-shifted digital content item is played via a playback screen, and an updateable companion timeline associated with the time-shifted digital content item is accessed. The updateable companion timeline includes one or more timeline events, and each timeline event has a trigger time corresponding to a playback time in the time-shifted digital content item. Responsive to reaching a playback time that matches a trigger time of one of the one or more timeline events during playback of the time-shifted digital content item, the timeline event having that trigger time is rendered.Type: ApplicationFiled: September 29, 2011Publication date: December 20, 2012Applicant: MICROSOFT CORPORATIONInventors: Matthew Fuller Sly, Jeffrey Lupien, Keh-Li Sheng, Howard Benjamin Nager
-
Publication number: 20110009343Abstract: Compounds that modulate the aggregation of amyloidogenic proteins or peptides are disclosed. The modulators of the invention can promote amyloid aggregation or, more preferably, can inhibit natural amyloid aggregation. In a preferred embodiment, the compounds modulate the aggregation of natural ? amyloid peptides (?-AP). In a preferred embodiment, the ? amyloid modulator compounds of the invention are comprised of an A? aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural ? amyloid peptides when contacted with the peptides. Furthermore, the modulators are capable of altering natural ?-AP aggregation when the natural ?-APs are in a molar excess amount relative to the modulators. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.Type: ApplicationFiled: December 21, 2009Publication date: January 13, 2011Applicant: Praecis Pharmaceuticals, Inc.Inventors: Mark A. Findeis, Howard Benjamin, Marc B. Garnick, Malcolm L. Gefter, Arvind Hundal, Laura Kasman, Gary Musso, Ethan R. Signer, James Wakefield, Michael J. Reed
-
Patent number: 7658917Abstract: Compounds that modulate the aggregation of amyloidogenic proteins or peptides are disclosed. The modulators of the invention can promote amyloid aggregation or, more preferably, can inhibit natural amyloid aggregation. In a preferred embodiment, the compounds modulate the aggregation of natural ? amyloid peptides (?-AP). In a preferred embodiment, the ? amyloid modulator compounds of the invention are comprised of an A? aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural ? amyloid peptides when contacted with the peptides. Furthermore, the modulators are capable of altering natural ?-AP aggregation when the natural ?-APs are in a molar excess amount relative to the modulators. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.Type: GrantFiled: June 17, 2003Date of Patent: February 9, 2010Assignee: Praecis Pharmaceuticals, Inc.Inventors: Mark A. Findeis, Howard Benjamin, Marc B. Garnick, Malcolm L. Gefter, Arvind Hundal, Ethan R. Signer, James Wakefield, Laura Kasman, Gary Musso, Michael J. Reed
-
Publication number: 20080032896Abstract: Methods for identifying a compound that binds to a target are described. In general, the methods involve forming a first library comprising a multiplicity of peptides, identifying one or more peptides that bind to the target and determining a peptide motif therefrom, forming a second library comprising a multiplicity of compounds designed based on the peptide motif, selecting from the second library at least one compound that binds to the target, and determining the structure or structures of the at least one compound that binds to the target. Libraries of compounds based on a peptide motif and compounds identified by the methods of the invention are also disclosed.Type: ApplicationFiled: February 9, 2007Publication date: February 7, 2008Inventors: Howard Benjamin, Mark Findeis, Malcolm Gefter, Gary Musso, Ethan Signer
-
Publication number: 20040091904Abstract: Methods for identifying a compound that binds to a target are described. In general, the methods involve forming a first library comprising a multiplicity of peptides, identifying one or more peptides that bind to the target and determining a peptide motif therefrom, forming a second library comprising a multiplicity of compounds designed based on the peptide motif, selecting from the second library at least one compound that binds to the target, and determining the structure or structures of the at least one compound that binds to the target. Libraries of compounds based on a peptide motif and compounds identified by the methods of the invention are also disclosed.Type: ApplicationFiled: June 30, 2003Publication date: May 13, 2004Inventors: Howard Benjamin, Mark A. Findeis, Malcolm L. Gefter, Gary Musso, Ethan R. Signer
-
Publication number: 20040005307Abstract: Compounds that modulate the aggregation of amyloidogenic proteins or peptides are disclosed. The modulators of the invention can promote amyloid aggregation or, more preferably, can inhibit natural amyloid aggregation. In a preferred embodiment, the compounds modulate the aggregation of natural &bgr; amyloid peptides (&bgr;-AP). In a preferred embodiment, the &bgr; amyloid modulator compounds of the invention are comprised of an A&bgr; aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural &bgr; amyloid peptides when contacted with the peptides. Furthermore, the modulators are capable of altering natural &bgr;-AP aggregation when the natural &bgr;-APs are in a molar excess amount relative to the modulators. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.Type: ApplicationFiled: June 17, 2003Publication date: January 8, 2004Applicant: Praecis Pharmaceuticals, Inc.Inventors: Mark A. Findeis, Howard Benjamin, Marc B. Garnick, Malcolm L. Gefter, Arvind Hundal, Laura Kasman, Gary Musso, Ethan R. Signer, James Wakefield, Michael J. Reed
-
Publication number: 20030100007Abstract: Methods for identifying a compound that binds to a target are described. In general, the methods involve forming a first library comprising a multiplicity of peptides, identifying one or more peptides that bind to the target and determining a peptide motif therefrom, forming a second library comprising a multiplicity of compounds designed based on the peptide motif, selecting from the second library at least one compound that binds to the target, and determining the structure or structures of the at least one compound that binds to the target. Libraries of compounds based on a peptide motif and compounds identified by the methods of the invention are also disclosed.Type: ApplicationFiled: December 18, 1996Publication date: May 29, 2003Inventors: HOWARD BENJAMIN, MARK A. FINDEIS, MALCOLM L. GEFTER, GARY MUSSO, ETHAN R. SIGNER
-
Patent number: 6475806Abstract: An anchor library is described. A collection of recombinant vectors having a nucleic acid encoding a displayed peptide sequence is provided. The displayed peptide sequence of each of the vectors comprises X1(Y1)c1X2(Y2)c2X3(Y3)c3X4, wherein each X1, X2, X3 and X4 is an amino acid residue and any of X1, X2, X3 and X4 can be the same or different from any one other, wherein each Y1, Y2 and Y3 is alanine or glycine or a combination of alanine and glycine that is respectively c1, c2 and c3 amino acid residues long and any of Y1, Y2 and Y3 if present can be the same or different from any one other, wherein each of c1, c2 and c3 is 0 to about 20, wherein X1 and X4 are each attached to an amino acid residue that flanks the displayed peptide sequence. Preferably, at least about 105 to about 108 permutations of all possible permutations of the displayed peptide sequence are present in the anchor library.Type: GrantFiled: June 7, 1995Date of Patent: November 5, 2002Assignee: Praecis Pharmaceuticals, Inc.Inventors: Howard Benjamin, Ethan Signer, Malcolm Gefter
-
Publication number: 20020098173Abstract: Compounds that modulate the aggregation of amyloidogenic proteins or peptides are disclosed. The modulators of the invention can promote amyloid aggregation or, more preferably, can inhibit natural amyloid aggregation. In a preferred embodiment, the compounds modulate the aggregation of natural &bgr; amyloid peptides (&bgr;-AP). In a preferred embodiment, the &bgr; amyloid modulator compounds of the invention are comprised of an A&bgr; aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural &bgr; amyloid peptides when contacted with the peptides. Furthermore, the modulators are capable of altering natural &bgr;-AP aggregation when the natural &bgr;-APs are in a molar excess amount relative to the modulators. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.Type: ApplicationFiled: October 4, 2001Publication date: July 25, 2002Applicant: Praecis Pharmaceuticals, Inc.Inventors: Mark A. Findeis, Howard Benjamin, Marc B. Garnick, Malcolm L. Gefter, Arvind Hundal, Laura Kasman, Gary Musso, Ethan R. Signer, James Wakefield, Michael J. Reed
-
Patent number: 6319498Abstract: Compounds that modulate the aggregation of amyloidogenic proteins or peptides are disclosed. The modulators of the invention can promote amyloid aggregation or, more preferably, can inhibit natural amyloid aggregation. In a preferred embodiment, the compounds modulate the aggregation of natural &bgr; amyloid peptides (&bgr;-AP). In a preferred embodiment, the &bgr; amyloid modulator compounds of the invention are comprised of an A&bgr; aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural &bgr; amyloid peptides when contacted with the peptides. Furthermore, the modulators are capable of altering natural &bgr;-AP aggregation when the natural &bgr;-APs are in a molar excess amount relative to the modulators. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.Type: GrantFiled: March 14, 1996Date of Patent: November 20, 2001Assignee: Praecis Pharmaceuticals IncorporatedInventors: Mark A. Findeis, Howard Benjamin, Marc B. Garnick, Malcolm L. Gefter, Arvind Hundal, Laura Kasman, Gary Musso, Ethan R. Signer, James Wakefield, Michael J. Reed
-
Publication number: 20010006778Abstract: Methods for identifying a compound that binds to a target are described. In general, the methods involve forming a first library comprising a multiplicity of peptides, identifying one or more peptides that bind to the target and determining a peptide motif therefrom, forming a second library comprising a multiplicity of compounds designed based on the peptide motif, selecting from the second library at least one compound that binds to the target, and determining the structure or structures of the at least one compound that binds to the target. Libraries of compounds based on a peptide motif and compounds identified by the methods of the invention are also disclosed.Type: ApplicationFiled: January 26, 2001Publication date: July 5, 2001Applicant: Praecis Pharmaceuticals IncorporatedInventors: Howard Benjamin, Mark A. Findeis, Malcolm L. Gefter, Gary Musso, Ethan R. Signer
-
Patent number: 6214795Abstract: This invention provides peptide compounds that bind to either a fibroblast growth factor (FGF) or a fibroblast growth factor receptor (FGFR) and, accordingly, are useful for modulating FGFR activity. Preferably, the FGFR is FGFR2-IIIC. Preferably, the FGF is basic FGF. Preferably the peptide compound comprises an amino acid sequence: (Y/F)-(L/F/I)-(R/D/E/S/Y/G)-(Q/L/Y)-Y-(M/L/K/R)-(L/M/D/E/N/S)-(R/L/S/T)-(L/F/M/V) (SEQ ID NO: 1). The invention further comprises pharmaceutical compositions comprising the peptide compounds of the invention and a pharmaceutically acceptable carrier. The invention still further provides methods of modulating FGFR activity using the peptide compounds of the invention.Type: GrantFiled: November 12, 1996Date of Patent: April 10, 2001Assignee: Praecis Pharmaceuticals, Inc.Inventors: Howard Benjamin, Ling Chai, Mark A. Findeis, William Goodwin, Arvind Hundal, David I. Israel, Michael Kelley, Martin P. Keough, Kuanghui Lu, Farah Natoli, Alicia Peticolas, Ethan R. Signer, Malcolm L. Gefter
-
Patent number: 5854204Abstract: Compounds that modulate the aggregation of amyloidogenic proteins or peptides are disclosed. The modulators of the invention can promote amyloid aggregation or, more preferably, can inhibit natural amyloid aggregation. In a preferred embodiment, the compounds modulate the aggregation of natural .beta. amyloid peptides (.beta.-AP). In a preferred embodiment, the .beta. amyloid modulator compounds of the invention are comprised of an A.beta. aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural .beta. amyloid peptides when contacted with the peptides. Furthermore, the modulators are capable of altering natural .beta.-AP aggregation when the natural .beta.-APs are in a molar excess amount relative to the modulators. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.Type: GrantFiled: March 14, 1996Date of Patent: December 29, 1998Assignee: Praecis Pharmaceuticals, Inc.Inventors: Mark A. Findeis, Howard Benjamin, Marc B. Garnick, Malcolm L. Gefter, Arvind Hundal, Laura Kasman, Gary Musso, Ethan R. Signer, James Wakefield, Michael Reed, Susan Molineaux, William Kubasek, Joseph Chin, Jung-Ja Lee, Michael Kelley
-
Patent number: 5854215Abstract: Compounds that act to modulate the aggregation of natural .beta. amyloid peptides (.beta.-AP) are disclosed. The .beta. amyloid modulators of the invention can promote .beta.-AP aggregation or, more preferably, can inhibit natural .beta.-AP aggregation. Furthermore, the modulators are capable of altering natural .beta.-AP aggregation when the natural .beta.-APs are in a molar excess amount relative to the modulators. Pharmaceutical compositions comprising the compounds of the invention, and methods of altering natural .beta.-AP aggregation using the compounds of the invention, are also disclosed.Type: GrantFiled: June 7, 1995Date of Patent: December 29, 1998Assignee: Praecis Pharmaceuticals IncorporatedInventors: Mark A. Findeis, Howard Benjamin, Marc B. Garnick, Malcolm L. Gefter, Arvind Hundal, Laura Kasman, Gary Musso, Ethan R. Signer, James Wakefield, Michael J. Reed
-
Patent number: 5817626Abstract: Compounds that act to modulate the aggregation of natural .beta. amyloid peptides (.beta.-AP) are disclosed. The .beta. amyloid modulators of the invention can promote .beta.-AP aggregation or, more preferably, can inhibit natural .beta.-AP aggregation. Furthermore, the modulators are capable of altering natural .beta.-AP aggregation when the natural .beta.-APs are in a molar excess amount relative to the modulators. Preferred .beta. amyloid modulators comprise amino-terminally biotinylated .beta. amyloid peptide compounds. Pharmaceutical compositions comprising the compounds of the invention, and methods of altering natural .beta.-AP aggregation using the compounds of the invention, are also disclosed.Type: GrantFiled: March 14, 1995Date of Patent: October 6, 1998Assignee: Praecis Pharmaceuticals IncorporatedInventors: Mark A. Findeis, Howard Benjamin, Marc B. Garnick, Malcolm L. Gefter, Arvind Hundal, Laura Kasman, Gary Musso, Ethan R. Signer, James Wakefield, Michael J. Reed